Clinical Outcomes
Intended Audience: This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.
Credit Available: Up to 1.0 credit hour available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expired
Click Here to Review – CE ExpiredEDUCATIONAL OBJECTIVES
- Review the latest data supporting the use of rtCGM to improve patient outcomes and reduce resource utilization in T1 and T2D
- Assess the impact of social determinants of health (SDOH) on outcomes in diabetes among low-income and racial/ethnic minority populations
- Describe the role of diabetes technology in increasing patient engagement and self-management across diverse member populations of varying age, race/ethnicity, income, and insurance type
- Discuss the positive impact of electronic prior authorization for rtCGM under the pharmacy benefit in terms of provider administrative burden, access, and total cost of care
EXPERT FACULTY
Monica Peek, MD, MPH, MS
Professor of Medicine
Associate Director
Chicago Center for Diabetes Translational Research
The University of Chicago Medicine
Samir Mistry, PharmD, MBA
Vice President of Pharmacy Strategy & Services
Capital Blue Cross
Kelly Close
Founder, The diaTribe Foundation
President, Close Concerns
Dana McCormick, RPh, FMACP (Moderator)
Director of Pharmacy
Blue Cross Blue Shield of Texas
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This continuing education activity is supported by an independent educational grant from Dexcom, Inc.
This infographic recap of real-time continuous glucose monitoring (rtCGM) posters from the American Diabetes Association’s 82nd Scientific Sessions details where the latest cutting-edge advances in diabetes research, prevention, and care are presented. These posters highlight real-world evidence and are pertinent to managed care and payer decision makers for assessing the value of rtCGM in improving clinical outcomes, reducing avoidable healthcare utilization, and decreasing the burden of management.
This infographic recaps real-time continuous glucose monitoring (rtCGM) abstracts from the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) – where innovation in diabetes medicines and treatments, cutting-edge technologies, and the latest research is presented. These abstracts are pertinent to managed care and payer decision makers and help characterize the value of rtCGM in improving clinical outcomes, decreasing avoidable healthcare utilization, and decreasing the burden of diabetes care management.
In a retrospective claims analysis from Kaiser Permanente of Northern California, 149 patients with insulin-treated type 2 diabetes (T2D; baseline HbA1c <8%) who initiated real-time continuous glucose monitoring (RT-CGM) demonstrated durable glycemic benefit compared with 17,273 noninitiators serving as reference. RT-CGM initiation was associated with decreased HbA1c (-0.06%) while noninitiation was associated with increased HbA1c (+0.32%). A weighted adjusted difference-in-difference model of change in HbA1c yielded a net benefit of -0.30% (P=0.004) for RT-CGM. These findings highlight the notion that RT-CGM may be useful in preventing glycemic deterioration and offer a durable benefit in well-controlled patients with insulin-treated T2D.
Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. Continuous Glucose Monitor Use Prevents Glycemic Deterioration in Insulin-Treated Patients with Type 2 Diabetes. Diabetes Technol Ther. 2022;24(5):332-337.
Learn More
Source: Endocrine Today
“Our real-world study found that in patients with insulin-treated diabetes, initiating a continuous glucose monitor substantially improved blood glucose control and cut the rate of emergency room visits for hypoglycemia in half,”
Andre J . Karter, PhD
Learn More